Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 102
Filter
1.
Int J Oral Maxillofac Surg ; 52(8): 831-838, 2023 Aug.
Article in English | MEDLINE | ID: mdl-36639343

ABSTRACT

Up to 30% of oral squamous cell carcinoma (OSCC) patients develop local recurrence and distant metastasis. The molecular status of histologically cancer-free tumour margins could be a critical factor in predicting tumour behaviour. The aim of this study was to detect somatic genomic imbalances in OSCC with emphasis on the surgical margins. DNA was isolated from tumour tissues, margin tissues, and blood samples (used as control) obtained from 11 OSCC patients, and genome-wide array comparative genomic hybridization was performed. Imbalances were present in both tumours and margins, although, as expected, they were more prevalent in tumours (duplications, P = 0.0002; deletions, P = 0.0001). Duplications were more frequent than deletions in both tumours and margins, but without statistical significance. Fifteen imbalances in tumour tissues were recurrent and all of them were duplications. Four of these were found both in tumours and margins and involved chromosomes 1q, 8p, Xp, Yp, and Yq. Four imbalances were recurrent in margin tissue and all of them were duplications (autosomes 8 and 17 and both sex chromosomes). Histologically 'cancer-free' margins hide genomic alterations consistent with unexplained OSCC recurrences. Establishing the molecular status of the margins could improve outcome prediction.


Subject(s)
Carcinoma, Squamous Cell , Head and Neck Neoplasms , Mouth Neoplasms , Humans , Mouth Neoplasms/genetics , Mouth Neoplasms/surgery , Mouth Neoplasms/pathology , Carcinoma, Squamous Cell/genetics , Carcinoma, Squamous Cell/surgery , Carcinoma, Squamous Cell/pathology , Comparative Genomic Hybridization , Margins of Excision , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/pathology , Squamous Cell Carcinoma of Head and Neck , Genomics
2.
Transplant Proc ; 51(9): 2917-2920, 2019 Nov.
Article in English | MEDLINE | ID: mdl-31711577

ABSTRACT

The posology of tacrolimus (TAC) is usually guided by its therapeutic drug monitoring. Some patients reach target concentrations (CTs) quickly, others more slowly. In a retrospective study, 20 kidney transplant recipients were included (mean age, 50.7 ± 14.1 years; weight 64.0 ± 14.2 kg; patients clinically stable for over a year). We studied cytochrome CYP3A5 genotype, in particular CYP3A5 6986A>G, the most important polymorphism related to the metabolism of TAC (wild genotype CYP3A5 *1 genotype, and CYP3A5 *3 variants). One year after transplantation, the CTs were 5.0 to 8.0 ng/mL. The patients were divided into group A (TAC doses < 6.0 mg/d) and group B (TAC doses > 6.0 mg/d). All were tested for the CYP3A5 gene sequence to characterize their polymorphism. Patients with CYP3A5 *1/*1 and *1/*3 were extensive metabolizers, and those with CYP3A5 *3/*3 were poor metabolizers. In group A and group B, the average TAC doses at the time of therapeutic drug monitoring were 3.0 ± 1.4 ng/mL (0.05 ± 0.03 mg/kg) and 12.8 ± 3.7 ng/mL (0.2 ± 0.1 mg/kg), respectively (P < .001). Group A was the poor metabolizers genotype, while in group B, the extensive metabolizers genotype was present. Patients with the CYP3A5 *1/*1 or *1/*3 genotype required 1.5 to 2 times higher doses than patients *3/*3 to reach CT. This genetic test allows clinicians to know, before the kidney transplant, the patient's TAC metabolism pattern and then to optimize the drug exposure.


Subject(s)
Cytochrome P-450 CYP3A/genetics , Immunosuppressive Agents/metabolism , Immunosuppressive Agents/therapeutic use , Kidney Transplantation , Tacrolimus/metabolism , Tacrolimus/therapeutic use , Adult , Aged , Drug Monitoring , Female , Genotype , Graft Rejection/prevention & control , Humans , Male , Middle Aged , Polymorphism, Genetic , Precision Medicine/methods , Retrospective Studies
3.
BMC Ophthalmol ; 17(1): 107, 2017 Jun 28.
Article in English | MEDLINE | ID: mdl-28659124

ABSTRACT

BACKGROUND: We report the ophthalmic findings of a patient with type Ia glycogen storage disease (GSD Ia), DiGeorge syndrome (DGS), cataract and optic nerve head drusen (ONHD). CASE PRESENTATION: A 26-year-old white woman, born at term by natural delivery presented with a post-natal diagnosis of GSD Ia. Genetic testing by array-comparative genomic hybridization (CGH) for DGS was required because of her low levels of serum calcium. The patient has been followed from birth, attending the day-hospital every six months at the San Paolo Hospital, Milan, outpatient clinic for metabolic diseases and previously at another eye center. During the last day-hospital visit, a complete eye examination showed ONHD and cataract in both eyes. Next Generation Sequencing (NGS) was subsequently done to check for any association between the eye problems and metabolic aspects. CONCLUSIONS: This is the first description of ocular changes in a patient with GSD Ia and DGS. Mutations explaining GSD Ia and DGS were found but no specific causative mutation for cataract and ONHD. The metabolic etiology of her lens changes is known, whereas the pathogenesis of ONHD is not clear. Although the presence of cataract and ONHD could be a coincidence; the case reported could suggest that hypocalcemia due to DGS could be the common biochemical pathway.


Subject(s)
Cataract/etiology , DiGeorge Syndrome/complications , Glycogen Storage Disease/complications , Optic Disk Drusen/etiology , Visual Fields , Adult , Cataract/diagnosis , Comparative Genomic Hybridization , DiGeorge Syndrome/diagnosis , Female , Glycogen Storage Disease/diagnosis , High-Throughput Nucleotide Sequencing , Humans , Optic Disk Drusen/diagnosis , Tomography, Optical Coherence , Visual Acuity
5.
Endocrine ; 45(1): 148-52, 2014 Feb.
Article in English | MEDLINE | ID: mdl-23636804

ABSTRACT

The presence of the sodium/iodide symporter (NIS) is the prerequisite for the use of the radioiodine in the treatment of thyroid cancer. Thus, stimulators of NIS expression and function are currently investigated in cellular models of various human malignancies, also including extrathyroid cancers. In this study, we analyzed the effects of the histone deacetylase inhibitors (HDACi), suberoylanilide hydroxamic acid (SAHA) and valproic acid (VPA), on NIS expression and function in rat Leydig testicular carcinoma cells (LC540). LC540 cells were exposed to SAHA 3 µM and VPA 3 mM (alone and in combination), and cell viability evaluated by MTT assay and cell counting, NIS mRNA and protein levels by using, respectively, real-time RT-PCR and western blotting. NIS function was evaluated by iodide uptake assay. We found that both HDACi were able to stimulate the transcription of NIS gene, but not its protein expression, while the association of SAHA and VPA increased both NIS transcript and protein levels, resulting in significant sixfold enhancement of radioiodine uptake capacity of LC540 cells. These data demonstrate the presence of an epigenetic control of NIS expression in Leydig tumor cells, suggesting the possibility to use the combination of these two HDACi for a radioiodine-based treatment of these malignancies.


Subject(s)
Histone Deacetylase Inhibitors/pharmacology , Hydroxamic Acids/pharmacology , Leydig Cell Tumor/pathology , Symporters/genetics , Testicular Neoplasms/pathology , Valproic Acid/pharmacology , Animals , Cell Line, Tumor , Cells, Cultured , Drug Evaluation, Preclinical , Drug Synergism , Gene Expression/drug effects , Leydig Cell Tumor/drug therapy , Leydig Cell Tumor/genetics , Male , Rats , Symporters/physiology , Testicular Neoplasms/drug therapy , Testicular Neoplasms/genetics , Vorinostat
6.
Oncogene ; 33(22): 2876-87, 2014 May 29.
Article in English | MEDLINE | ID: mdl-23831574

ABSTRACT

Nucleophosmin 1 (NPM1) is a nucleolar protein involved in ribosome biogenesis, stress responses and maintaining genome stability. One-third of acute myeloid leukemias (AMLs) are associated with aberrant localization of NPM1 to the cytoplasm (NPM1c+). This mutation is critical during leukemogenesis and constitutes a good prognostic factor for chemotherapy. At present, there is no clear molecular basis for the role of NPM1 in DNA repair and the tumorigenic process. We found that the nuclear apurinic/apyrimidinic endonuclease 1 (APE1), a core enzyme in base excision DNA repair (BER) of DNA lesions, specifically interacts with NPM1 within nucleoli and the nucleoplasm. Cytoplasmic accumulation of APE1 is associated with cancers including, as we show, NPM1c+ AML. Here we show that NPM1 stimulates APE1 BER activity in cells. We provide evidence that expression of the NPM1c+ variant causes cytoplasmic accumulation of APE1 in: (i) a heterologous cell system (HeLa cells); (ii) the myeloid cell line OCI/AML3 stably expressing NPM1c+; and (iii) primary lymphoblasts of NPM1c+ AML patients. Consistent with impaired APE1 localization, OCI/AML3 cells and blasts of AML patients have impaired BER activity. Cytoplasmic APE1 in NPM1c+ myeloid cells is truncated due to proteolysis. Thus, the good prognostic response of NPM1c+ AML to chemotherapy may result from the cytoplasmic relocalization of APE1 and the consequent BER deficiency. NPM1 thus has an indirect but significant role in BER in vivo that may also be important for NPM1c+ tumorigenesis.


Subject(s)
DNA-(Apurinic or Apyrimidinic Site) Lyase/metabolism , Neoplasms/metabolism , Nuclear Proteins/metabolism , Cell Line, Tumor , Cytoplasm/metabolism , DNA Damage , DNA Repair , Gene Expression , Gene Knockout Techniques , HeLa Cells , Humans , Leukemia, Myeloid, Acute/genetics , Leukemia, Myeloid, Acute/metabolism , Models, Biological , Mutation , Neoplasms/genetics , Nuclear Proteins/genetics , Nucleophosmin , Protein Binding , Protein Stability , Protein Transport
7.
Clin. transl. oncol. (Print) ; 15(1): 65-71, ene. 2013. tab, ilus
Article in English | IBECS | ID: ibc-126969

ABSTRACT

AIM AND BACKGROUND: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase involved in many important aspects of cell biology that are related to tumorigenesis. There are opposite evidences of the role of EGFR in renal cancer and the outcome of EGFR-targeted therapies, suggesting the complexity of EGFR signaling pathways. In vitro, osteopontin (OPN) and nuclear factor kappa B (NF-κB) are thought to be involved in specific ligand-independent EGFR activation that could have a role in resistance to EGFR mAb therapy. Aim of this study was to analyze the relationship between EGFR and OPN at the protein and mRNA level, as well as their relation to NF-κB in clear cell renal cell carcinoma (CCRCC). MATERIALS AND METHODS: Expression of EGFR, OPN, and p65 NF-κB protein was analyzed using immunohistochemistry and compared mutually in 88 CCRCC samples. Expression of EGFR and OPN mRNAs was analyzed using quantitative Real-time PCR in 22 CCRCC samples and compared mutually and with NF-κB protein expression. RESULTS: Epidermal growth factor receptor mRNA level was higher in CCRCC samples in comparison with normal renal tissue (p = 0.012) and was associated with high OPN mRNA level, and with NF-κB activation (p < 0.001 and p = 0.045, respectively). Immunohistochemical staining showed the inverse association; high EGFR protein expression was related with low OPN and NF-κB protein expression (p < 0.001 and p = 0.047, respectively). CONCLUSION: Epidermal growth factor receptor gene is upregulated in CRCC and associated with OPN gene expression and NF-kB signaling. The inverse relation between OPN and EGFR at the protein level could probably reflect dynamic changes that EGFR undergoes following activation (AU)


Subject(s)
Humans , Carcinoma, Renal Cell/genetics , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , Immunohistochemistry , NF-kappa B/genetics , NF-kappa B/metabolism , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Kidney Neoplasms/genetics , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , Osteopontin/genetics , Osteopontin/metabolism , ErbB Receptors/genetics , ErbB Receptors/metabolism
8.
Clin Transl Oncol ; 15(1): 65-71, 2013 Jan.
Article in English | MEDLINE | ID: mdl-22855173

ABSTRACT

AIM AND BACKGROUND: Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase involved in many important aspects of cell biology that are related to tumorigenesis. There are opposite evidences of the role of EGFR in renal cancer and the outcome of EGFR-targeted therapies, suggesting the complexity of EGFR signaling pathways. In vitro, osteopontin (OPN) and nuclear factor kappa B (NF-κB) are thought to be involved in specific ligand-independent EGFR activation that could have a role in resistance to EGFR mAb therapy. Aim of this study was to analyze the relationship between EGFR and OPN at the protein and mRNA level, as well as their relation to NF-κB in clear cell renal cell carcinoma (CCRCC). MATERIALS AND METHODS: Expression of EGFR, OPN, and p65 NF-κB protein was analyzed using immunohistochemistry and compared mutually in 88 CCRCC samples. Expression of EGFR and OPN mRNAs was analyzed using quantitative Real-time PCR in 22 CCRCC samples and compared mutually and with NF-κB protein expression. RESULTS: Epidermal growth factor receptor mRNA level was higher in CCRCC samples in comparison with normal renal tissue (p = 0.012) and was associated with high OPN mRNA level, and with NF-κB activation (p < 0.001 and p = 0.045, respectively). Immunohistochemical staining showed the inverse association; high EGFR protein expression was related with low OPN and NF-κB protein expression (p < 0.001 and p = 0.047, respectively). CONCLUSION: Epidermal growth factor receptor gene is upregulated in CRCC and associated with OPN gene expression and NF-kB signaling. The inverse relation between OPN and EGFR at the protein level could probably reflect dynamic changes that EGFR undergoes following activation.


Subject(s)
Carcinoma, Renal Cell/genetics , ErbB Receptors/genetics , Kidney Neoplasms/genetics , NF-kappa B/metabolism , Osteopontin/genetics , Carcinoma, Renal Cell/metabolism , Carcinoma, Renal Cell/pathology , Cell Line, Tumor , ErbB Receptors/metabolism , Humans , Immunohistochemistry , Kidney Neoplasms/metabolism , Kidney Neoplasms/pathology , NF-kappa B/genetics , Osteopontin/metabolism , RNA, Messenger/metabolism , Real-Time Polymerase Chain Reaction , Signal Transduction , Up-Regulation
9.
J Neuroendocrinol ; 24(6): 916-29, 2012 Jun.
Article in English | MEDLINE | ID: mdl-22356123

ABSTRACT

Thyroid transcription factor 1 (TTF1), a member of the Nkx family of transcription factors required for basal forebrain morphogenesis, functions in the postnatal hypothalamus as a transcriptional regulator of genes encoding neuromodulators and hypophysiotrophic peptides. One of these peptides is gonadotrophin-releasing hormone (GnRH). In the present study, we show that Ttf1 mRNA abundance varies in a diurnal and melatonin-dependent fashion in the preoptic area of the rat, with maximal Ttf1 expression attained during the dark phase of the light/dark cycle, preceding the nocturnal peak in GnRH mRNA content. GnRH promoter activity oscillates in a circadian manner in GT1-7 cells, and this pattern is enhanced by TTF1 and blunted by small interfering RNA-mediated Ttf1 gene silencing. TTF1 transactivates GnRH transcription by binding to two sites in the GnRH promoter. Rat GnRH neurones in situ contain key proteins components of the positive (BMAL1, CLOCK) and negative (PER1) limbs of the circadian oscillator, and these proteins repress Ttf1 promoter activity in vitro. By contrast, Ttf1 transcription is activated by CRY1, a clock component required for circadian rhythmicity. In turn, TTF1 represses transcription of Rev-erbα, a heme receptor that controls circadian transcription within the positive limb of the circadian oscillator. These findings suggest that TTF1 is a component of the molecular machinery controlling circadian oscillations in GnRH gene transcription.


Subject(s)
Circadian Rhythm/genetics , Gene Expression Regulation/genetics , Gonadotropin-Releasing Hormone/physiology , Homeodomain Proteins/physiology , Nuclear Proteins/physiology , Trans-Activators/physiology , Transcription Factors/physiology , Animals , Circadian Rhythm/physiology , Gonadotropin-Releasing Hormone/biosynthesis , Gonadotropin-Releasing Hormone/genetics , Nuclear Proteins/biosynthesis , Nuclear Proteins/genetics , Rats , Rats, Sprague-Dawley , Thyroid Nuclear Factor 1 , Transcription Factors/biosynthesis , Transcription Factors/genetics
10.
Ann Oncol ; 20(2): 265-71, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18765464

ABSTRACT

BACKGROUND AND AIM: Capecitabine is an orally bioavailable prodrug that is converted to 5-fluorouracil through several enzymatic steps, the last of which is mediated by thymidine phosphorylase (TP). TP has been reported to be expressed at higher levels in cancer tissue compared with normal counterpart. The present study aimed at evaluating the potential relationship between TP expression and benefit from capecitabine in patients with metastatic breast cancer (BC). METHODS: Immunohistochemistry for TP and other biological markers was carried out on paraffin-embedded cancer tissues of 61 patients with BC treated with at least three cycles of capecitabine as single agent for metastatic disease. All patients had received capecitabine 1000 mg/m(2) b.i.d. days 1-14 every 21 days. The following variables were analyzed as potential determinants of benefit from capecitabine: TP expression, estrogen receptor (ER) and progesterone receptor status, human epidermal growth factor receptor-2 (HER-2) status, MIB-1 expression, performance status at the beginning of capecitabine treatment, stage at diagnosis, grade, presence of visceral metastases at the beginning of capecitabine treatment, and previous chemotherapy. RESULTS: Overall, median time to progression (TTP) was 6.5 months (range 1.4-33). On multivariate analysis, ER status [hazard ratio (HR) for progression = 0.31; 95% confidence interval (CI) = 0.15-0.64; P = 0.002], presence of visceral metastases at the beginning of capecitabine treatment (HR = 2.30; 95% CI = 1.21-4.39; P = 0.01), and capecitabine as first- or second-line treatment (HR = 2.28; 95% CI = 1.21-4.32; P = 0.01) independently predicted TTP. TP was highly expressed in 34 of 61 cases (55.7%). In the subgroup of patients with TP-expressing tumor, TTP was significantly longer in patients who received anthracyclines and taxanes before capecitabine (median TTP 7.5 versus 3.3 months, P = 0.01, log-rank test). Similarly, patients with a TP-positive tumor showed a longer TTP if they received taxanes before capecitabine than patients with TP-positive tumor who did not receive this treatment (7.3 versus 3.4 months, P = 0.03). CONCLUSIONS: These data provide further evidence that TP expression in BC could represent a biomarker of sensitivity to capecitabine treatment. Prospective studies with translational approach are desirable to confirm the predictive and prognostic role of TP.


Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/enzymology , Deoxycytidine/analogs & derivatives , Fluorouracil/analogs & derivatives , Thymidine Phosphorylase/metabolism , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/analysis , Biomarkers, Tumor/metabolism , Breast Neoplasms/pathology , Capecitabine , Deoxycytidine/therapeutic use , Disease Progression , ErbB Receptors/metabolism , Female , Fluorouracil/therapeutic use , Follow-Up Studies , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , Middle Aged , Multivariate Analysis , Neoplasm Metastasis , Prognosis , Receptor, ErbB-2/metabolism , Receptors, Estrogen/metabolism , Receptors, Progesterone/metabolism , Retrospective Studies , Thymidine Phosphorylase/analysis , Time Factors , Treatment Outcome , Ubiquitin-Protein Ligases/metabolism
11.
Ann Oncol ; 19(9): 1541-6, 2008 Sep.
Article in English | MEDLINE | ID: mdl-18441329

ABSTRACT

BACKGROUND: Preclinical data have indicated a synergistic interaction between docetaxel and capecitabine by means of taxane-induced up-regulation of thymidine phosphorylase (TP). On the basis of such premises, we conducted a phase II trial to determine the activity and tolerability of weekly docetaxel plus capecitabine in patients with metastatic breast cancer (MBC). Furthermore, we explored the relationship between TP tumor expression and benefit from this regimen. PATIENTS AND METHODS: Patients received docetaxel 36 mg/m(2) i.v. on days 1, 8, and 15 and capecitabine orally 625 mg/m(2) b.i.d. from days 8 to 21. Cycles were repeated every 4 weeks. In the correlative study, we evaluated the TP expression by immunohistochemistry and the TP messenger RNA expression by real-time RT-PCR in the primary tumor. RESULTS: Forty-seven women were enrolled. In the intention-to-treat analysis, objective responses were achieved in 24 patients (51%). Fourteen additional patients (30%) had stable disease. The median time to progression (TTP) was 6 months (range 1-44 months). Median survival was 17 months (range 1-48 months). Overall, the treatment was well tolerated. The most common clinical adverse events (all grades) were alopecia (55%), nail changes (53%), fatigue/asthenia (51%), nausea/vomiting (51%), neutropenia (49%), and neuropathy (49%). A significantly higher TTP was observed in patients with TP-positive tumors (log-rank test, P = 0.009). Interestingly, a subgroup analysis confirmed this TTP benefit in patients with TP-positive tumors obtaining a tumor response (log-rank test, P = 0.03), whereas the statistical significance was lost in nonresponders (log-rank test, P = 0.3). CONCLUSIONS: This study indicates that a regimen with low doses of capecitabine plus weekly docetaxel is active against MBC. The correlative analysis provides preliminary evidence that TP expression may be a predictive marker for therapeutic benefit.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Biomarkers, Tumor/metabolism , Breast Neoplasms/drug therapy , Breast Neoplasms/enzymology , Carcinoma, Ductal/secondary , Carcinoma, Lobular/secondary , Thymidine Phosphorylase/metabolism , Administration, Oral , Adult , Aged , Alopecia/chemically induced , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Biomarkers, Tumor/analysis , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Capecitabine , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Deoxycytidine/analogs & derivatives , Disease Progression , Docetaxel , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Synergism , Female , Fluorouracil/administration & dosage , Fluorouracil/adverse effects , Fluorouracil/analogs & derivatives , Gastrointestinal Diseases/chemically induced , Hematologic Diseases/chemically induced , Humans , Infusions, Intravenous , Liver Neoplasms/secondary , Maximum Tolerated Dose , Middle Aged , Neoplasm Invasiveness/pathology , Neoplasm Staging , Prognosis , Risk Assessment , Sensitivity and Specificity , Survival Analysis , Taxoids/administration & dosage , Taxoids/adverse effects , Thymidine Phosphorylase/analysis , Treatment Outcome , Up-Regulation
12.
J Clin Pathol ; 61(4): 494-8, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17938160

ABSTRACT

BACKGROUND: Periostin is a secreted adhesion protein, normally expressed in mesenchime-derived cells. Aberrant expression of the periostin gene in epithelial tumours seems to play a role in angiogenesis and metastases. AIMS: To investigate periostin expression in a consecutive series of breast carcinomas and correlate it with established biological and prognostic factors. METHODS: A consecutive series of 206 breast carcinomas was investigated by immunohistochemistry with a specific antiperiostin antibody. Immunohistochemical expression of oestrogen and progesterone receptors, Ki-67 (MIB-1), HER-2/neu, VEGF-A, VEGFR-1 and VEGFR-2 was analysed. Periostin expression was also investigated in MCF-7 and MDA-468 cell lines by immunohistochemistry, western blot and quantitative RT-PCR. Localisation of periostin was investigated in MCF-7 cells by the green fluorescent protein (GFP) approach. RESULTS: Periostin was highly expressed in carcinoma cells, but not in normal breast tissues. The pattern of expression was mainly cytoplasmic. However, in 12% of cases a nuclear reactivity was observed. Nuclear periostin significantly correlated with tumour size, and with expression of oestrogen receptor, progesterone receptor, VEGF-A, VEGFR-1 and VEGFR-2. A nuclear localisation of periostin was also observed in MCF-7 and MDA-468 cell lines. In MCF-7 cells the nuclear localisation of periostin was also shown by transfection of a vector expressing a GFP-periostin chimeric protein. CONCLUSIONS: Results indicate that the aberrant gene expression of periostin in breast cancer cells is associated with an abnormal nuclear localisation of the protein. The nuclear localisation of periostin in breast cancer may induce significant biological effects.


Subject(s)
Biomarkers, Tumor/metabolism , Breast Neoplasms/metabolism , Carcinoma, Ductal, Breast/metabolism , Carcinoma, Lobular/metabolism , Cell Adhesion Molecules/metabolism , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Cell Adhesion Molecules/genetics , Cell Nucleus/metabolism , Cytoplasm/metabolism , Female , Humans , Neoplasm Invasiveness , Neoplasm Proteins/metabolism , Polymerase Chain Reaction/methods , Prognosis , RNA, Messenger/genetics , RNA, Neoplasm/genetics , Transfection , Tumor Cells, Cultured
13.
Cancer Invest ; 24(6): 611-4, 2006 Oct.
Article in English | MEDLINE | ID: mdl-16982466

ABSTRACT

Carriers of BRCA2 germline mutation have a significantly increased lifetime risk of breast and ovarian cancer compared to non carriers. Several other carcinomas seem to be associated with BRCA2 mutations: pancreas, prostate, larynx, gallbladder, bile duct cancer, and malignant melanoma. We described a case of a 67-year-old BRCA2 mutation carrier of Caucasian, non-Jewish, ethnic origin who successively developed 4 primary malignancies in 30 months: breast ductal carcinoma, chronic lymphatic leukemia, ovarian serous papillary carcinoma, and endocervical adenocarcinoma. This is the first case of 4 primary malignancies in a BRCA mutation carrier, also occurred in such a short observation period. Chronic lymphatic leukemia and endocervical adenocarcinoma have not been yet associated to BRCA2 germline mutation.


Subject(s)
BRCA2 Protein/genetics , Breast Neoplasms/genetics , Germ-Line Mutation , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Neoplasms, Multiple Primary/genetics , Ovarian Neoplasms/genetics , Uterine Cervical Neoplasms/genetics , Adenocarcinoma/genetics , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Aged , Breast Neoplasms/pathology , Breast Neoplasms/therapy , Carcinoma, Ductal, Breast/genetics , Carcinoma, Ductal, Breast/pathology , Carcinoma, Ductal, Breast/therapy , Cystadenocarcinoma, Papillary/genetics , Cystadenocarcinoma, Papillary/pathology , Cystadenocarcinoma, Papillary/therapy , Cystadenocarcinoma, Serous/genetics , Cystadenocarcinoma, Serous/pathology , Cystadenocarcinoma, Serous/therapy , Female , Genetic Predisposition to Disease , Humans , Leukemia, Lymphocytic, Chronic, B-Cell/pathology , Leukemia, Lymphocytic, Chronic, B-Cell/therapy , Male , Middle Aged , Neoplasms, Multiple Primary/pathology , Neoplasms, Multiple Primary/therapy , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Pedigree , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/therapy
14.
Minerva Ginecol ; 58(2): 171-5, 2006 Apr.
Article in Italian | MEDLINE | ID: mdl-16582871

ABSTRACT

Genetic investigation of BRCA1 and BRCA2 germline mutations is, nowadays, a diagnostic procedure with practical clinical applications. The role of this genes in DNA repair and stability and in cancer development is now well recognised. Most involved are breast and ovarian cancers, but, less frequently, other gynecological cancers like cervical, corpus uteri and Fallopian tubes cancers and also other non gynecological malignancies. We report the case of a 67-year-old patient with strong familiarity for breast cancer, with a BRCA2 germline mutation, who developed in 30 months 4 primary malignancies: in chronological order, breast cancer, chronic lymphatic leukemia, and synchronous ovarian and endocervical adenocarcinoma. A better knowledge of the biological and clinical behaviour of BRCA related cancers is of strategical importance in the management of patients with strong familiar neoplastic history or with genetic test positivity. An adequate counselling can help in the management of these cancers in the prevention and early diagnosis taking also into consideration the possibility of a prophylactic surgery.


Subject(s)
Adenocarcinoma/genetics , BRCA1 Protein/genetics , BRCA2 Protein/genetics , Breast Neoplasms/genetics , Leukemia, Lymphocytic, Chronic, B-Cell/genetics , Neoplasms, Multiple Primary/genetics , Ovarian Neoplasms/genetics , Uterine Cervical Neoplasms/genetics , Aged , Female , Humans , Mutation , Pedigree
15.
J Endocrinol Invest ; 28(2): 137-44, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15887859

ABSTRACT

Differential protein arrays between nuclear extracts of human thyroid cell lines obtained from tumors with different degree of differentiation were exploited to define molecular alterations occurring during thyroid tumor progression. Nuclear extracts from the well differentiated TPC-1 (from papillary carcinoma) and the poorly differentiated ARO (from anaplastic carcinoma) cells showed an overall similar pattern of protein expression as revealed by two-dimensional gel electrophoresis analysis. However, manganese-superoxide dismutase (Mn-SOD) was clearly identified by mass spectrometry procedures as significantly less expressed in ARO compared to TPC-1 cells. A reduced expression of Mn-SOD in the nuclear compartment was confirmed by Western blot and immunofluorescence analysis. A similar expression pattern of nuclear Mn-SOD was detected by immunohistochemistry in human thyroid tumors, with the lowest or absent detection in anaplastic carcinomas. Moreover, the levels of nuclear Mn-SOD in tumor cells were lower than in the normal thyrocytes. These data indicate that an altered nuclear expression of Mn-SOD parallels, together with changes in other elements of the antioxidant protective system, the loss of differentiation occurring during the progression of thyroid tumors.


Subject(s)
Carcinoma/enzymology , Cell Nucleus/enzymology , Proteomics , Superoxide Dismutase/metabolism , Thyroid Neoplasms/enzymology , Thyroid Neoplasms/pathology , Adenocarcinoma, Follicular/enzymology , Adenocarcinoma, Follicular/pathology , Blotting, Western , Carcinoma/pathology , Carcinoma, Papillary/enzymology , Carcinoma, Papillary/pathology , Cell Line, Tumor , Fluorescent Antibody Technique , Humans , Immunohistochemistry , In Vitro Techniques , Tissue Distribution
16.
Int J Gynaecol Obstet ; 88(3): 265-70, 2005 Mar.
Article in English | MEDLINE | ID: mdl-15733879

ABSTRACT

OBJECTIVE: The aim of this study was to evaluate the correlation between genetic thrombophilic mutations, uterine artery Doppler at 24 weeks of gestation and preeclampsia. METHODS: In a case control study we performed the genetic analysis for Leiden mutation of factor V gene (FV), G20210A mutation of the prothrombin gene (PT) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene in 103 women that had already attended routine ultrasonography scanner at 20 weeks at our Department. RESULTS: The frequency of heterozygous carriers of the factor V Leiden was 17.4% in the women with preeclampsia and abnormal artery Doppler compared with 3.12% in the patients with normal pregnancies. This difference was statistically significant (P<0.05). The frequency of mutation G20210A of prothrombin gene was 1.5 vs. 4.3% between women with normal pregnancies and with preeclampsia. This difference is not statistically significant. The frequency of homozygous patients for the C677T mutation of MTHFR gene among the patients with preeclampsia was 21.7% and in the control group was 10.3%, but this difference is not statistically significant. No thrombophilic gene variants were found in women with preeclampsia and normal uterine artery Doppler. CONCLUSION: We demonstrated the important association between factor V Leiden mutation, abnormal uterine Doppler at 24 weeks and preeclampsia in our population.


Subject(s)
Factor V/genetics , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Pre-Eclampsia/physiopathology , Prothrombin/genetics , Uterus/blood supply , Adult , Case-Control Studies , Female , Humans , Laser-Doppler Flowmetry , Mutation , Pre-Eclampsia/diagnosis , Pre-Eclampsia/genetics , Pregnancy , Ultrasonography, Prenatal
17.
J Mol Endocrinol ; 34(1): 199-207, 2005 Feb.
Article in English | MEDLINE | ID: mdl-15691888

ABSTRACT

Tumour suppressor p53 is a transcription factor essential for DNA damage checkpoints during cellular response to stress. Mutations in the p53 gene are the most common genetic alterations found in human tumours; most pathogenetic modifications are missense mutations that abolish the p53 DNA-binding function. In the same cell type, distinct p53 missense mutations may determine different phenotypes. The PC Cl3 cell line retains several markers of thyroid differentiation in vitro. Introduction of the V143A mutant p53 allele, which abolishes the p53 DNA-binding function, leads to loss of differentiation markers as well as TSH dependency for growth. Conversely, PC Cl3 cells transfected with the S392A mutant p53 allele, presenting the mutation located outside the DNA-binding domain, show only loss of TSH dependency for growth. To identify molecular differences existing between PC Cl3 cell lines transformed by the V143A and the S392A mutant alleles, a differential proteomic approach was used. Two-dimensional gel electrophoresis analyses indicated that expression of a significant portion of protein species was modified by both p53 mutants. In fact, compared with wild-type PC Cl3 cells, modification of expression in V143A mutant cells occurred in 23.6% of the entire protein species. Conversely, modification of S392A mutant cells affected 14.0% of total proteins. Among these components, 8.3% were common to both mutants. Several of these proteins were identified by mass spectrometry procedures; some proteins, such as HSP90 and T-complex proteins, are already known to be related to p53 function.


Subject(s)
Cell Transformation, Neoplastic/metabolism , Neoplasm Proteins/metabolism , Thyroid Gland/metabolism , Calreticulin/isolation & purification , Electrophoresis, Gel, Two-Dimensional , Galectin 1/isolation & purification , HSP90 Heat-Shock Proteins/isolation & purification , Humans , Neoplasm Proteins/isolation & purification , Proteome , Tumor Suppressor Protein p53/metabolism , Vimentin/isolation & purification
18.
Minerva Ginecol ; 56(5): 385-90, 2004 Oct.
Article in Italian | MEDLINE | ID: mdl-15531855

ABSTRACT

AIM: Pre-eclampsia is one of the major causes of maternal and fetal morbidity and mortality. The aim of this study was to evaluate the clinical usefulness of screening of genetic thrombophilic mutations and uterine artery Doppler flow velocimetry at 24 weeks of gestation in the prediction of pre-eclampsia in low risk pregnant women. METHODS: We performed the genetic analysis for Leiden mutation of factor V gene (FV), G20210A mutation of the prothrombin gene (PT) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene in 103 women that had already attended routine ultrasonography scanner at 24 weeks at our Department. RESULTS: The frequency of heterozygous carriers of the Leiden FV was 17.4% in women with pre-eclampsia and abnormal artery Doppler flow velocimetry compared with 3.12% in patients with normal pregnancies. This difference was statistically significant (P<0.05). The frequency of mutation G20210A of PT gene was 1.5% vs 4.3% between women with normal pregnancies and with pre-eclampsia. This difference is not statistically significant. The frequency of homozygous patients for the C677T mutation of MTHFR gene among patients with pre-eclampsia was 21.7% and in the control group was 10.3%, but this difference is not statistically significant. No thrombophilic genes variants were found in women with pre-eclampsia and normal uterine artery Doppler flow velocimetry. CONCLUSION: We demonstrated the important association between FV Leiden mutation, abnormal uterine artery Doppler flow velocimetry at 24 weeks and pre-eclampsia in our low-risk population.


Subject(s)
Factor V/genetics , Mass Screening , Methylenetetrahydrofolate Reductase (NADPH2)/genetics , Mutation , Pre-Eclampsia/diagnostic imaging , Pre-Eclampsia/genetics , Prothrombin/genetics , Uterus/blood supply , Adult , Biomarkers/metabolism , Case-Control Studies , Female , Humans , Mass Screening/methods , Methylenetetrahydrofolate Reductase (NADPH2)/blood , Polymerase Chain Reaction , Pre-Eclampsia/blood , Pregnancy , Pregnancy Trimester, Second , Pulsatile Flow , Retrospective Studies , Risk Factors , Ultrasonography, Doppler/methods , Uterus/diagnostic imaging
19.
Horm Metab Res ; 35(1): 24-8, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12669267

ABSTRACT

Relaxin is a peptide hormone that, in humans, is encoded by two genes referred to as H1 and H2, both located into chromosome 9p24.1. We have searched for polymorphisms in the 5'-flanking sequence of these genes. Both genes possess a CT repeat followed by a GT repeat. CT and GT repeats of the H2 gene are longer than those of the H1 gene. Moreover, CT and GT repeats of the H2 gene, but not those of the H1 gene, show length polymorphism. Protein-DNA interaction experiments suggest that difference between the H1 and H2 GT repeats may have arisen because the requirements of the transcriptional regulation of the two genes are different.


Subject(s)
5' Flanking Region/genetics , Dinucleotide Repeats/genetics , Polymorphism, Genetic/genetics , Relaxin/genetics , Actins/genetics , DNA Probes , Gene Expression Regulation , Humans , Microsatellite Repeats , Polymorphism, Single-Stranded Conformational , Reverse Transcriptase Polymerase Chain Reaction
20.
Mol Cell Endocrinol ; 194(1-2): 71-6, 2002 Aug 30.
Article in English | MEDLINE | ID: mdl-12242029

ABSTRACT

Apurinic/apyrimidinic endonuclease APE/Ref-1 is a multifunctional protein provided with DNA repair, transcription-factor regulation and anti-apoptotic activities. We have previously reported that, in thyroid cells, TSH regulates both the synthesis and nuclear translocation of APE/Ref-1. We have also shown that nuclear levels of this protein are reduced both in thyroid carcinoma tissues and cell lines. In the present study, APE/Ref-1 expression and cellular localization were analysed by Western blot in hyperfunctioning thyroid nodules from patients with toxic adenoma and/or toxic multinodular goiter. The total content of APE/Ref-1 protein was increased in the majority of the hyperfunctioning tissues with respect to normal adjacent tissue. There was also an increase in the nuclear levels of APE/Ref-1, suggesting enhanced cytoplasm-to-nucleus translocation of the protein in addition to its increased rate of synthesis. These results demonstrate that the phenomenon of nuclear translocation of APE/Ref-1 hypothesized on the basis of cell culture experiments does actually occur in vivo. Together with previous observations in thyroid carcinomas and tumoral cell lines, our findings suggest a two-stage model of APE/Ref-1 behaviour during malignant thyrocyte transformation: an early stage characterized by simple hyperplasia and upregulation of APE/Ref-1 in the nuclear compartment of the cell and a later stage in which nuclear levels of the protein drop to below-normal levels as the cell becomes progressively undifferentiated.


Subject(s)
Carbon-Oxygen Lyases/biosynthesis , Thyroid Nodule/pathology , Active Transport, Cell Nucleus , Adenoma/pathology , Aged , Carbon-Oxygen Lyases/analysis , Carbon-Oxygen Lyases/metabolism , Cell Nucleus/enzymology , Cell Transformation, Neoplastic/chemistry , DNA-(Apurinic or Apyrimidinic Site) Lyase , Female , Goiter, Nodular/pathology , Humans , Male , Middle Aged , Protein Transport , Thyroid Nodule/enzymology , Up-Regulation
SELECTION OF CITATIONS
SEARCH DETAIL
...